BioSpace News Archive

Astrocyte Pharmaceuticals Inc. has announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead program, AST-004, for acute ischemic stroke.

Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.

Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present new findings at the AACR Annual Meeting, which will take place April 5 to 10 in San Diego.

Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction.

Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2023.

Neurona Therapeutics today announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will present a corporate update on Tuesday, March 19 at 5:00 pm ET and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place on March 19-20, 2024.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the publication, in Cardiovascular Diabetology, of an independent, peer-reviewed study utilizing its MyoVista® proprietary technology.

Epicore Biosystems announced today that it successfully completed its System and Organization Controls (SOC) 2 Type II compliance in accordance with the American Institute of Certified Public Accounts (AICPA).